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To the Editors:
Firstly, we would like to thank you for the opportunity to 
respond to the issues raised in Prof. Lewczuk et al.’s Letter to 
the Editors [1] and to clarify the aim of our paper [2]. 
We would also like to thank Lewczuk et al. for their inter-
est in our paper and for taking time to express their comments 
[1]. We acknowledge the importance of cerebrospinal fluid 
(CSF) biomarkers in multiple sclerosis (MS), especially oli-
goclonal bands. In their Letter, the authors explain in detail 
oligoclonal bands’ methodology and note concerns about 
an insufficient approach to MS biomarkers’ methodology in 
our paper. 
  However, the primary objective of our review was to focus 
on prospective and future biomarkers in MS not, due to limited 
space, to discuss in detail currently available biomarkers that 
have been already reviewed previously [3–6]. Therefore, we 
thank Lewczuk et al. for their valuable comments. These will be 
an additional resource for readers interested in MS biomarkers. 
Ultimately, we agree with the authors that continued re-
search into MS biomarkers is needed to fully understand the 
pathogenesis of this disease and improve diagnostics. 
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